New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 24, 2014
04:55 EDTEW, EW, EW, EW, EW, QDEL, QDEL, QDEL, QDEL, QDEL, SQNM, SQNM, SQNM, SQNM, SQNM, TNDM, TNDM, TNDM, TNDM, TNDM, VOLC, VOLC, VOLC, VOLC, VOLC, ATEC, ATEC, ATEC, ATEC, ATEC, CFN, CFN, CFN, CFN, CFN, ICUI, ICUI, ICUI, ICUI, ICUI, IART, IART, IART, IART, IART, ELGX, ELGX, ELGX, ELGX, ELGX, NUVA, NUVA, NUVA, NUVA, NUVAPiper Jaffray to hold a bus tour
7th Annual SoCal Medtech & Diagnostics Bus Tour to travel throughout San Diego on August 25-28.
News For EW;ELGX;IART;ICUI;CFN;ATEC;VOLC;TNDM;SQNM;QDEL;NUVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 30, 2014
05:29 EDTNUVANuVasive upgraded to Buy from Hold at Brean Capital
Subscribe for More Information
September 29, 2014
12:57 EDTVOLCVolcano confirms receipt of Engaged Capital letter
Subscribe for More Information
12:18 EDTELGXOn The Fly: Midday Wrap
Subscribe for More Information
11:39 EDTELGXEndologix plummets to 52-week low after cutting outlook
Subscribe for More Information
08:31 EDTVOLCEngaged Capital calls on Volcano board to evaluate strategic alternatives
Subscribe for More Information
07:24 EDTELGXStephens to hold an investor trip
Subscribe for More Information
07:09 EDTELGXEndologix reports preliminary Q3 revenue approximately $37M, consensus $37.68M
Subscribe for More Information
07:07 EDTELGXEndologix lowers FY14 adjusted EPS view to (43c)-(37c) from (33c)-(27c)
Subscribe for More Information
06:56 EDTELGXEndologix completes enrollment in EVAS FORWARD Global Registry
Subscribe for More Information
06:51 EDTELGXEndologix to initiate prospective randomized EVAR clinical study
Endologix announced that it will conduct the first ever prospective randomized clinical study to compare outcomes in endovascular repair of abdominal aortic aneurysms. The LEOPARD Study has been designed to provide an accurate and unbiased assessment of commercially available EVAR devices with a planned enrollment of 600 patients. LEOPARD will include up to 60 active EVAR centers throughout the United States. The primary endpoint of the study is treatment success at one year based upon: procedural success; and rates of freedom from aneurysm rupture; conversion to open surgical repair; endoleaks; clinically significant device migration; aneurysm enlargement and secondary endovascular procedures. Results from the study will be independently adjudicated by a third-party. The follow-up period will be five years.
September 25, 2014
10:13 EDTEWHigh option volume stocks
Subscribe for More Information
06:34 EDTEWEdwards Lifesciences price target raised to $120 from $95 at Piper Jaffray
Piper Jaffray raised its price target for Edwards Lifesciences shares to $120 saying recent Transcatheter Aortic Valve Replacement market momentum is likely to continue. The firm keeps an Overweight rating on the stock.
September 22, 2014
07:05 EDTSQNMSequenom presents new data supporting accuracy of MaterniT21 test
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, presented patient clinical data substantiating the performance of its MaterniT21 PLUS noninvasive prenatal test in the laboratory. An ad hoc analysis of 185,000 samples from patients at high-risk for fetal chromosome aneuploidy demonstrated stable positivity rates for trisomy 21, 18 and 13, which mirror the positivity rates found in large studies on high-risk populations utilizing invasive diagnostic procedures. Additionally, Sequenom Laboratories reported performance results from clinical testing with the MaterniT21 PLUS test with Enhanced Sequencing Series. In the ad hoc analysis based on voluntary outcomes provided by clinicians, the estimated sensitivity for trisomy 21, 18 and 13 were 99.3%, 98.3% and 97.4% respectively, and the estimated specificity was >99.9% for all three trisomies. These clinical laboratory performance data are equivalent to those published in the clinical validation studies of the MaterniT21 test. Based on these performance metrics, Sequenom Laboratories estimates that the MaterniT21 PLUS test positive predictive value for trisomy 21, 18 and 13 were 99.0%, 97.6% and 92.8% respectively, and the negative predictive value was >99.9% for all three trisomies.
September 18, 2014
09:19 EDTEWGeneration Investment reports 5.2% passive stake in Edwards Lifesciences
08:38 EDTIARTIntegra LifeSciences announces commercial release of Integra Freedom system
Subscribe for More Information
05:44 EDTQDELFlu season could be stronger than expected, says Piper Jaffray
Subscribe for More Information
September 17, 2014
11:57 EDTSQNMSequenom management to meet with Maxim
Meetings to be held in New York on September 22 with a group luncheon also and in Boston on September 23 hosted by Maxim.
11:26 EDTIARTIntegra LifeSciences management to meet with Oppenheimer
Subscribe for More Information
07:27 EDTIARTIntegra LifeSciences price target raised to $68 from $59 at Piper Jaffray
Piper Jaffray raised its price target for shares of Integra LifeSciences to $68 saying meetings with the company's CEO increased its confidence in its Overweight rating. Piper thinks Integra's performance will improve in 2015 and expects the stock to significantly outperform over the next 12 months.
06:09 EDTIARTIntegra LifeSciences to acquire Medtronic instrumentation lines for $60M
Integra LifeSciences (IART) and Medtronic (MDT) announced an agreement in which Integra will acquire Medtronic's MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines for approximately $60M in cash. Integra expects the transaction to close in Q4. Integra will acquire a portfolio of approximately 4,000 MicroFrance and Xomed manual ENT and laparoscopic surgical instruments, as well as the St. Aubin le Monial, France manufacturing facility. Sales from the products being acquired totaled approximately $30M, two-thirds of which were generated outside the U.S. Integra expects to record approximately $27M-$30M in revenue and approximately 10c of adjusted EPS in calendar 2015 from this acquisition. The earnings accretion should rise after the first year once certain sales transitions are complete. The company expects the acquisition to contribute less than $5M in revenue and be neutral to earnings in Q4. The transition and integration is expected to be completed by 2H15.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use